CalciMedica, Inc.
CALC
Last
$1.27
Day
-3.1%
1y
-92.3%
5y
-81.4%
52w
-96.4%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1132d
EMA 21
1.74
EMA 50
2.31
EMA 200
5.67
20d high
-36.9%
5y high
-97.0%
5y range
0th
Positions held
Your positionsCALC isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$1.54
Stop
$1.10
Stop distance
13.4%
Target vs last
+21.3%
Fundamentals
| Market cap | $8.88M | Enterprise value | -$540,220 | Trailing P/E | — | Forward P/E | -0.80 |
| PEG | — | Price / book | 1.45 | Beta | 1.10 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.7% | ROA | -63.6% | Debt / equity | 1.67 |
| Current ratio | 5.58 | Free cash flow | -$10.54M | Analyst recommendation | none | Mean target | $50.00 |
| 52w high | $36.00 | 52w low | $1.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.7M | $5.0M | -$10.8M | -$7.8M | -$6.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.0M | -$5.6M | -$4.4M | -$5.6M | -$6.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$14.2M | — |
Headline scan
Headlines — watch
• [WARN · fundamentals] CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
News
2026-09-08 · CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-27 · CalciMedica Announces One-for-Five Reverse Stock Split
2026-08-11 · CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
2026-08-11 · CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-07-29 · CalciMedica Reaches FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis
Price (daily)
Full chart · RSI · MACD · patternsCALC · daily-30.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin